Dr. Benjamin L. Ebert

Dr. Benjamin L. Ebert, MD, PhD, is a renowned hematologist-oncologist and physician-scientist whose research has transformed the understanding of myeloid malignancies and hematopoiesis. He serves as Chair of Medical Oncology at the Dana-Farber Cancer Institute, where he also directs a leading laboratory in cancer biology. Dr. Ebert earned his medical degree from Harvard Medical School and completed his residency in internal medicine at Massachusetts General Hospital, followed by fellowship training in hematology and oncology at Dana-Farber. He also holds a PhD from the University of Oxford, where he studied as a Rhodes Scholar. He is board-certified in Hematology and Internal Medicine.

Dr. Ebert is internationally recognized for elucidating the mechanisms of action of lenalidomide in myelodysplastic syndromes (MDS) and for identifying the role of clonal hematopoiesis in cancer and cardiovascular disease. His lab discovered key mutations in RNA splicing and epigenetic regulators that underlie MDS and related hematologic disorders, significantly advancing diagnostic and therapeutic strategies. Dr. Ebert’s work on cereblon-mediated degradation has influenced the development of new classes of targeted therapies in hematologic cancers and has contributed to the rise of protein degradation as a drug development paradigm.

In addition to his laboratory accomplishments, Dr. Ebert is an esteemed mentor and academic leader. He has published extensively in Nature, NEJM, Cell, and Science, and his work has received numerous honors, including election to the National Academy of Medicine and the American Academy of Arts and Sciences. He has mentored a generation of investigators in translational hematology and remains a central figure in shaping the future of research and care in myeloid malignancies.